Xencor | XNCR - Operating Profit


Xencor reported $-77.86M in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
AbbVie USD 4.73B 1.08B Mar/2026
Alnylam Pharmaceuticals USD 137.59M 108.19M Mar/2026
Amgen USD 3.83B 130M Mar/2026
Arrowhead Research USD -141.26M 182.07M Mar/2026
AstraZeneca USD 7.11B 4.14B Mar/2026
Biogen USD 514.3M 128.8M Mar/2026
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Cytokinetics USD -181.23M 2.86M Mar/2026
GlaxoSmithKline GBP 2.29B 856M Mar/2026
J&J USD 6.62B 1.03B Mar/2026
Karyopharm Therapeutics USD -17.84M 13.44M Dec/2025
MacroGenics USD -12.1M 30.74M Dec/2025
Merck USD -1.88B 8.12B Mar/2026
Novartis USD 4.24B 171M Mar/2026
Pfizer USD 4.99B 340M Mar/2026
Regeneron Pharmaceuticals USD 744.8M 153.8M Mar/2026
Roche Holding CHF 9.56B 3.8B Dec/2025
Xencor USD -77.86M 24.23M Mar/2026